Risks

·      No Revenue, very recent IPO with very little business history (Artrya founded in 2018)

·      Competitive industry -Artrya could face competitors able to spend more on R&D and marketing etc.

·      Healthcare industry is highly regulated

Easy pass for us, until can prove it can earn revenue and scale.

Key Strengths

·      Global Problem - heart disease is the world’s biggest killer, responsible for one in three deaths globally. With population growth and ageing, the burden on the total healthcare system and the consequent need for medical imaging services to detect coronary artery disease is forecast to continue rising.

·      Growing Market - Demand is being driven by global population growth and ageing societies.

·      Scalable Business Model - Salix products are delivered through a SaaS business model. Being cloud-based, Salix solutions are securely accessible 24 hours a day, seven days per week wherever internet services are available. The software is available on a subscription basis, requires no hardware installation and is highly scalable, delivering a high gross margin business model.

·      Two Founders continue to Lead business with John Barrington as CEO and John Konstantopoulos as Executive director of Product. Both have skin in the game John Barrington as 7,526,095 shares (9.62% shares on issue) and John Konstantopoulos 7,000,000 shares (8.95 shares on issue)